Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 765 participants.
Also called NCT03789552
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 765 participants
- Sponsor
- Tasly Pharmaceuticals, Inc.
- Registry
-
NCT03789552
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT03789552. Randomized; quadruple masking; primary purpose treatment. Start 2019-08-01 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
- Condition
- Chronic Stable Angina Pectoris
- Intervention (Drug)
- T89 capsule
- Intervention (Drug)
- Placebo capsule
- Lead sponsor
- Tasly Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct03789552- Content hash
ed400b919044b5576b1ea3ebb336b4476dca5ecb82ee81655c710e1ce5cc3a90